UCP2 and mitochondrial haplogroups as a multiple sclerosis risk factor

Multiple Sclerosis

Volumn 13, Issue 4, 2007, Pages 454-458

  Otaegui, David ^a   Saenz, A ^a   Ruiz Martinez J ^b   Olaskoaga, J ^a   Lopez de Munain A ^a  

^a HOSPITAL DONOSTIA   (Spain)

^b HOSPITAL DE MENDARO   (Spain)

Author keywords

Association; Basque; Mitochondrial haplogroups; Multiple sclerosis; Multiple Sclerosis Severity Score; UCP2

Indexed keywords

UNCOUPLING PROTEIN 2;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; AGE OF ONSET; ETHNIC GROUPS; HUMANS; ION CHANNELS; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL PROTEINS; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SPAIN;

EID: 34249081073     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070454     Document Type: Article

References (25)

1. Hauser SL, Goodin D. Multiple sclerosis and other demyelinating diseases. In Braunwald eds. Harrison's principles in internal medicine. McGraw Hill, 2005: 2461-71.
2. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001; 113: 171-84.
3. Haskin Fernald G, Ru-Fang Y, Hauser SL, Oksenberg J, Baranzini SE. Mapping gene activity in complex disorders: integration of expression and genomic scans for multiple sclerosis. J Neuroimmunol 2005; 167: 157-59.
4. Baranzini SE, Oksenberg JR. Genomics and new targets for multiple sclerosis. Pharmacogenomics 2005; 6: 151-61.
5. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000; 157: 637-45.
6. Vogler S, Goedde R, Miterski B, Gold R, Kroner A, Koczan D et al. Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J Mol Med 2005; 83: 806-11.
7. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28: 178-83.
8. Sasahara M, Nishi M, Kawashima H, Ueda K, Sakagashira S, Furuta H et al. Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients. Diabetes 2004; 53: 482-85.
9. Ruiz-Pesini E, Lapena. AC, Diez-Sanchez C, Perez-Martos A, Montoya J, Alvarez E et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000; 67: 682-96.
10. Reynier P, Penisson-Besnier I, Moreau C, Savagner F, Vielle B, Emile J et al. mtDNA haplogroup J: a contributing factor of optic neuritis. Eur J Hum Genet 1999; 7: 404-46.
11. Otaegui D, Saenz A, Martinez-Zabaleta M, Villoslada P, Fernandez-Manchola I, Alvarez DA et al. Mitochondrial haplogroups in Basque multiple sclerosis patients. Mult Scler 2004; 10: 532-35.
12. Rodríguez-Antiguedad AR. Esclerosis múltiple, análisis clínico retrospectivo y prospectivo de una serie hospitalaria de base poblacional. UPV/EHU, 1999.
13. Mallada-Frechin J. Epidemiología descriptiva de la esclerosis múltiple en Españia. Cuademos de Esclerosis Múltiple 2003; 16: 1-15.
14. Instituto Nacional de Estadística (INE) (España). 2005, www.ini.es
15. McDonald W, Compston A, Edan G, Goodkin DE, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel of the diagnosis of multiple sclerosis. Ann Neurol 2001; 5O: 121-27.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis. An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 144-52.
17. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-51.
18. Ruiz-Pesini E, Lapena. AC, Diez-Sanchez C, Perez-Martos A, Montoya J, Alvarez E et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000; 67: 682-96.
19. Calafell F, Bertranpetit J. Principal component analysis of gene frequencies and the origin of Basques. Am J Phys Anthropol 1994; 93: 201-15.
20. Bertranpetit J, Sala J, Calafell F, Underhill PA, Moral P, Comas D. Human mitochondrial DNA variation and the origin of Basques. Ann Hum Genet 1995; 59: 63-81.
21. Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A et al. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001; 124: 1927-38.
22. Horvath TL, Diano S, Barnstable C. Mitochondrial uncoupling protein 2 in the central nervous system: neuromodulator and neuroprotector. Biochem Pharmacol 2003; 65: 1917-21.
23. Diano S, Matthews RT, Patrylo P, Yang L, Beal MF, Barnstable CJ et al. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 2003; 144: 5014-21.
24. Vogler S, Pahnke J, Rousset S, Ricquier D, Moch H, Miroux B et al. Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis. Am J Pathol 2006; 168: 1570-75.
25. Ruiz-Pesini E, Lapena AC, Diez-Sanchez C, Perez-Martos A, Montoya J, Alvarez E et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000; 67: 682-96.